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Effect of mutations on the sensitivity of human beta-cell
glucokinase to liver regulatory protein
M. Veiga-da-Cunha 1, L. Z. Xu 2, Y.-H. Lee 2, D. Marotta 2, S. J. Pilkis 2., E. Van Schaftingen 1
1Laboratory of PhysiologicalChemistry, Institute of Cellular and Molecular Pathology and Universit6 Catholique de Louvain,
Brussels, Belgium
2Department of Biochemistry,Medical School, University of Minnesota, Minneapolis, Minnesota, USA

Summary Human beta-cell glucokinase and its liver
counterpart displayed a half-saturating concentration
of glucose (S0.s) of about 8 mmol/l and a Hill coefficient of 1.7, and were as sensitive to inhibition by the
rat liver regulatory protein as the rat liver enzyme.
These results indicate that the N-terminal region of
glucokinase, which differs among these three enzymes, is not implicated in the recognition of the regulatory protein. They also suggest that the regulatory
protein, or a related protein, could modulate the affinity of glucokinase for glucose in beta cells. We
have also tested the effect of several mutations,
many of which are implicated in maturity onset diabetes of the young. The mutations affected the affinity for glucose and for the regulatory protein to different degrees, indicating that the binding site for these
molecules is different. An AsplSSAla mutation, found

in the expression plasmid previously thought to encode the wild-type enzyme, increased the affinity for
glucose by about 2.5-fold without changing the affinity for the regulatory protein. The mutations that
were found to decrease the affinity for the regulatory
protein (Asn166Arg, ValZ°3Ala, AsnZ°4Gln, Lys414Ala)
clustered in the hinge region of glucokinase and nearby in the large and small domains. These results are in
agreement with the concept that part of the binding
site for the regulatory protein is situated in the hinge
region of this enzyme. [Diabetologia (1996) 39:
1173-1179]

Mammalian liver contains a protein inhibitor of glucokinase, which acts competitively with respect to glucose [1-2]. The effect of this regulatory protein is enhanced by fructose 6-phosphate and counteracted by
fructose 1-phosphate, both of which act by binding to
the inhibitor protein [3]. The regulatory protein inhibits glucokinase by forming a complex with this enzyme;
kinetic experiments have suggested that glucokinase
has distinct binding sites for the regulatory protein
and the substrate analogue N-acetylglucosamine [4].

The regulatory protein is specific for glucokinase;
it is found in the livers of species that express glucokinase and is absent in species in which glucokinase is absent [5]. Its presence in islets is inferred
from the observations that glucokinase activity in islet homogenates is slightly increased by fructose 1phosphate and that islet homogenates inhibit rat liver glucokinase in a fructose 1-phosphate-sensitive
manner [6]. Direct demonstration of the presence
of the regulatory protein in islet tissue is, however,
still lacking. Glucokinase partially purified from islet extracts is sensitive to the rat liver regulatory
protein, but the paucity of the enzyme does not permit a detailed kinetic analysis of the effect of the
regulatory protein on islet glucokinase [6]. Betacell glucokinase differs from its liver counterpart
[7] by the first 15 amino acids encoded by exon 1
or 1 ' [8].
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T h e availability of r e c o m b i n a n t h u m a n beta-cell
glucokinase [9] has m a d e it possible to study m o r e
carefully the kinetic effects of rat liver r e g u l a t o r y
protein. In this report, we have also investigated the
sensitivity of various glucokinase mutants, s o m e of
which are f o u n d in m a t u r i t y onset diabetes of the
y o u n g ( M O D Y ) [9-13], to the r e g u l a t o r y p r o t e i n to
ascertain w h e t h e r these m u t a t i o n s alter the affinity
for glucose to the same e x t e n t as the affinity for the
r e g u l a t o r y protein. While this w o r k was in progress,
it was f o u n d that the r e c o m b i n a n t c l o n e f r o m which
the expression vectors for h u m a n islet and h u m a n liver glucokinases w e r e d e r i v e d c o n t a i n e d a m u t a t i o n
replacing Asp 158 [14, 15] by an alanine residue. We
h a v e also investigated the effect of this m u t a t i o n .

40-

C
E

30-

'¢-

_

r::
•

20-

>

1

m

0

2'o

'

;o

'

6'o

'

8'o

'

1;o

Glucose (mrnol/I)

Fig.l. Effect of different concentrations of rat liver regulatory
protein on the glucose saturation curve of wild type recombinant human islet glucokinase

Materials and methods
The regulatory protein was purified from rat liver up to the hydroxylapatite step [16] and was freed of inorganic phosphate
by gel filtration on Sephadex G-25. Rat liver glucokinase was
purified from livers as described previously [9]. The preparation of recombinant forms of human liver and human betacell glucokinase (which are actually Asp158Ala mutants), and
of the site-directed mutants of the latter enzyme was reported
previously [9-12]. It should be noted that the construction of
the Asn~66Arg mutant led to the reversion of Ala I5s to an Asp
residue. The true wild-type enzymes were prepared by "repairing" the Ala 158 mutation according to the following site-directed mutagenesis procedure. The 5' (up to nucleotide 480)
and the 3' (from nucleotide 48I) coding regions of the human
beta-cell glucokinase cDNA inserted in pBlueScript KS +
(pBS-HIGKAsp158Ala) were amplified in two separate PCR
reactions with Pwo DNA polymerase using as primers T7 and
5' - ATCGATATCTTCGTGCCTCAC - 3', for the 5' region
and T3 and 5' - AAGGGCATCCTTCTCAACTGG - 3', for
the 3' region. The glucokinase-specific primers (mismatches
underlined) were phosphorylated at their Y-ends. The amplified fragments (560 and 1355 base pairs [bp]) were restricted
with Xba I and Barn HI, respectively, and purified by agarose
gel electrophoresis. They were then simultaneously ligated in
pBS that had been restricted with both XbaI and BamHI,
and the resulting construct was used to transform Escherichia
coli JM 109. The glucokinase insert was checked by sequencing
to exclude polymerase chain reaction (PCR) errors. The expression vector for human wild-type beta-cell glucokinase
(pET-HIGKAla158Asp) was then constructed by replacing a
SacII-SacI fragment in the expression vector coding for human beta-cell glucokinase Asp~SSAla by the corresponding "repaired" fragment. The expression vector for human wild-type
liver glucokinase (pET-HLGKAla]SSAsp) was similarly constructed. These "repaired" cDNAs were subsequently used to
transform E. coli BL21(DE3) pLysS [17] and the recombinant
proteins were expressed and purified as described [18].
Glucokinase was assayed spectrophotometrically at 30 °C in
a mixture containing, except where otherwise indicated,
25 mmol/1 Hepes, pH 7.1, 5 mmol/1 glucose, i mmol/l ATE
1 mmol/1 MgCI2, 1 mmol/1 dithiothreitol, 200 ~tmol/1 fructose
6-phosphate, 25 mmol/1 KC1, 0.25 mmol/1 phosphoenolpyruvate, 0.15 mmol/1 NADH, 10 ~tg/ml of rabbit muscle lactate dehydrogenase and of pyruvate kinase (desalted by gel filtration).
For the determination of the affinity of glucokinase for the
regulatory protein, care was taken to use low concentrations

of glucokinase (< 160 pg/1) to avoid overestimation of the true
affinity constants [16]. For the analysis of glucose saturation
curves, the Vmax was estimated on Hanes plots from values observed at high concentrations of substrate (typically 50300 mmol/1) and S05 values on Hill plots.

Results
Effect o f the regulatory protein on the kinetics o f the
wild-type enzyme. For the kinetic studies, glucokinase
was assayed at p H 7 . 1 and in the p r e s e n c e of
25 mmol/1 KC1. T h e s e conditions are optimal to study
the effect of the r e g u l a t o r y p r o t e i n b e c a u s e a h i g h e r
p H or higher c o n c e n t r a t i o n of C1- would a n t a g o n i z e
its effect [4]. Figure 1 shows that, as for rat liver glucokinase, the glucose s a t u r a t i o n curve of the wildtype h u m a n beta-cell glucokinase was sigmoidal, displaying u n d e r o u r assay conditions a S0.5 of approxim a t e l y 8 mmol/1 and a Hill coefficient close t o 1.7.
Figure 1 also shows that rat liver r e g u l a t o r y protein caused an increase in the S0.5 value w i t h o u t
changing Vmax, i.e., that the r e g u l a t o r y p r o t e i n beh a v e d as a c o m p e t i t i v e inhibitor. Plots of 1/v as a
function of the c o n c e n t r a t i o n of inhibitor at different
c o n c e n t r a t i o n s of glucose w e r e linear and their extrapolations crossed at a value of a b o u t - 0 . 8 U of
r e g u l a t o r y p r o t e i n / m l (Fig.2). B a s e d on these results,
it was c o n c l u d e d that the c o m p e t i t i v e inhibition constant of beta-cell glucokinase was 0.8 U r e g u l a t o r y
protein/ml, i. e. 4 nmol/1 [16]. A similar value was obt a i n e d with rat liver glucokinase (results not shown).
As previously r e p o r t e d for rat liver glucokinase [1],
the inhibition e x e r t e d by the r e g u l a t o r y p r o t e i n was
m o d u l a t e d by fructose 6 - p h o s p h a t e , which increased
the inhibition, and by fructose 1-phosphate which ant a g o n i z e d the inhibition (data not shown). Thus, in
the p r e s e n c e of 3.2 U of r e g u l a t o r y p r o t e i n per ml, a
half-maximal effect of fructose 6 - p h o s p h a t e was obs e r v e d at a c o n c e n t r a t i o n of a b o u t 10 ~tmol/1. A t the
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Fig.2. Dixon plot of the inhibition of wild type human islet
glucokinase by the rat liver regulatory protein. The activity
was measured in the presence of 3 (©), 5 (O), 10 (&) or 20
(A) retool/1 glucose

same concentration of regulatory protein and in the
presence of 50 ~tmol/1 fructose 6-phosphate, 20 ~tmol/1
fructose 1-phosphate was n e e d e d to release half of
the inhibition. KC1 and, to a lesser extent, potassium
acetate were found to release the inhibition exerted
by the regulatory protein on beta-cell glucokinase
(data not shown) with similar sensitivities to those previously observed with rat liver glucokinase [4].

Affinity of glucokinase mutants for glucose and Nacetyl-glucosamine. It was of interest to determine

Fig. 3 a, b. Hill plot (a) Hanes plot (b) of the glucose saturation
curve of wild type human islet glucokinase. The activity of the
human islet glucokinase was determined at different concentrations of glucose under the assay conditions described in
Methods. Data are the means of triplicates + SEM. In (b), the
regressions shown have been calculated for three sets of glucose concentrations in retool/l: 1)5 to 20, 2)7.5 to 30 and
3) 20 to 50; the KmS derived from these regressions were 17.9
and 5 mmol/1, respectively
1.0
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the sensitivity of the various mutant forms of glucokinase to the inhibition exerted by the regulatory protein. Since some of the mutations alter the affinity
for glucose and the regulatory protein behaves as a
competitive inhibitor, it was important to determine
the affinity for the regulatory protein under comparable conditions, i.e. at similar degrees of glucose saturation. The half-saturating concentrations of glucose
were determined graphically on Hill plots, as exemplified in Figure 3 a for the wild-type beta-cell enzyme. It is apparent that this type of plot was linear
and that it allowed the safe calculation of the half-saturating concentration of substrate (8 mmol/l) and the
Hill coefficient (1.7). Since some authors have analysed glucokinase kinetics by assuming Michaelis-Menten kinetics [9-13], we also show the results as Hanes
plots (Fig. 3 b). As expected for a sigmoidal enzyme,
this type of plot was curvilinear and different KrnS
(from 5 to 17 mmol/1 in the example) could be calculated depending on the set of data points considered.
Table 1 lists the S0.5 values that we observed under
our experimental conditions. They differ from the K m
values reported previously [9-13], but this is most
likely due to the fact that the kinetics were previously
analysed assuming Michaelis-Menten kinetics. Furthermore, some of the proteins tested in this work
and previously [9-12] are actually double-mutants.
For the Lys414Ala and the Cys414Glu m u t a n t s we observed that the inclusion of 25 mmol/1 KC1 in the assay markedly decreased the $0.5 value (from 16 to
2.3 mmol/1 and from 22 to 4.2 mmol/1, respectively),
whereas no such effect was observed with the wildtype enzymes.
The human beta cell and liver enzymes had the
same affinities for glucose, the S0.5 values of the nonmutated forms being almost identical to that of rat
liver glucokinase ( - 8 mmol/1), while the S0.5 of the
enzymes with the Asp158Ala mutation was about
2.5 fold lower. A n S0.5 value of approximately
3.5 mmol/1 was also observed with this mutant under
the assay conditions of Lange et al. [19]. The mutant
with the lowest affinity for glucose was the
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Table 1. Kinetic properties of rat liver glucokinase and of recombinant wild type and mutant forms of human islet and liver glucokinases
Glucokinase

So.5
(mmol/1)

Rat liver
Human islet wild type
Human islet AsplSSAla
Human liver wild type
Human liver Asp158Ala
Asn166Arg
VallS2Meta,AsplSSAla
Val2°3Alaa, AsplSSAla
AsnZ°4Gln,Aspa58Ala

GluZ79Glna,Asp158Ala
Lys4~4Ala,AspI58Ala
Lys414Glua, AsplSSAla

8
7.6/7.8
3.27 + 0.15 (3)
7.8/8
3.3/3.4
2.7 ± 0.06 (3)
20.1 + 0.7 (3)
38.5/39.5
200 _+26 (4)
19.3 _+0.33 (3)
2.3 ± 0.17 (3)
4.2

h

1.74
1.75/1.7
1.73 ± 0.03 (3)
1.6/1.75
1.75/1.6
1.22/1.22
1.62/1.8
1.44/1.37
1.06 ± 0.02
1.34 ± 0.06 (3)
1.45 ± 0.01 (3)
1.37

The effect of the regulatory protein was tested at 5 mmol/1 glucose or at the concentration indicated in the last column. This
was also the concentration used to estimate the half inhibitory
concentration of N-acetylglucosamine (I50NAG). Results are

[Regulatory protein] causing 50 %
inhibition

I50NAG
(mmol/1)

[Glucose]
(mmol/1)

at 5 mmol/l
glucose (U/ml)
1
1/1 (2)
5.4 _+0.42 (3)
1/1.1 (2)
5.57 _+0.03 (3)
6.53 ± 0.57 (3)
0.67 _+0.04 (3)
30/30 (2)
n.d.
1.89 ± 0.07 (4)
14/15 (2)
6.3

0.20
0.20
0.22
0.20
0.22
0.25
0.40
0.50
> 20
0.60
0.18
0.18

8
8
3.3
8
3.3
3
20
40
200
20
2.3
3

at indicated
[Glucose](U/ml)
2.1 _+0.3 (4)
2.4/2.6 (2)
2.4/2.8 (2)
2.4/2.5 (2)
2.4/3.0(2)
3.92 ± 0.4 (3)
1.57 + 0.09 (3)
31/32 (2)
24/22 (2)
3.13 + 0.13 (3)
8.0/7.6 (2)
3.8

individual values or the means _+SEM for (n) values. The values shown for the inhibition by N-acetylglucosamine were supported by other measurements performed at other glucose
concentrations, a Mutations found in subjects with MODY

concentration of glucose close to the So.5 value. For
the Valt82Met, the Val2°3Ala, the Asn2°4Gln and the
Glu279Gln mutants, the decrease in the affinity for
glucose was accompanied by a decrease in the affinity
for N-acetylglucosamine. Little change in affinity for
this inhibitor was h o w e v e r observed with the other
mutants, including the Asp15SAla proteins.

2oiO ,
0

Affinity of glucokinase mutants for the regulatory protein and for palmitoylCoA. The sensitivity of the wild-

,
110

2'.0 ' 3'.0 ' 4'.0 '
PalmitoylCoA (pmol/I)

5'.0

'

6'.0

Fig. 4. Effect of palmitoylCoA on the activity of wild type rat
liver and human beta-cell glucokinase and of various mutants.
The enzymes were assayed at concentrations of glucose close
to their S05 values (Table 1). (©) Rat liver GK; ( • ) wild type
islet glucokinase; (lI ) Asn~66Arg; (A) AsplSSAla, Val2°3Ala;
([]) Asp158Ala, Glu279Gln; (A) AsplsaAla, LysalaAla. All the
other glucokinases present in Table f but not shown in this figure behaved like the wild type beta-cell glucokinase except the
mutant Lys414Glu which had an intermediate behaviour

Asn2°4Gln, which was the only one in this series to
display hyperbolic kinetics, as indicated by a Hill
coefficient close to 1. O t h e r mutations (VallSZMet,
Val2°3Ala, GluZ79Gln) had decreased affinities for glucose but without i m p o r t a n t changes in the sigmoid
character of their glucose saturation curves.
The affinity for N-acetylglucosamine was determined by measuring the concentration of the aminosugar required to inhibit glucokinase by 50 % at a

type and m u t a n t glucokinases to inhibition by the regulatory protein was d e t e r m i n e d b o t h at a fixed glucose concentration (5 mmol/1 glucose) and at a glucose concentration close to the So.5 value d e t e r m i n e d
u n d e r our experimental conditions. The latter is
expected to reflect the affinity for the regulatory protein i n d e p e n d e n t of changes in the affinity for glucose. Care was t a k e n to use concentrations of glucokinase lower t h a n the dissociation constant of the glucokinase/regulatory protein complex (3 x 10 -9 mol/1)
to avoid overestimation of the inhibition constants
[16]. It should be n o t e d that the Asp158Ala m u t a t i o n
did not result in a change in the affinity for the regulatory protein. F o u r mutations (Asn166Arg, Val2°3Ala,
Asn2°4Gln, and Lysal4Ala) caused a significant decrease (> 1.5-fold) in the affinity for the regulatory
protein while the VallSZMet m u t a t i o n slightly increased this affinity. These changes did not always
parallel those in the affinity for glucose or N-acetylglucosamine. I n d e e d the Valt82Ala m u t a n t , which
had a decreased affinity for both glucose and Nacetylglucosamine, showed an increased affinity for
the regulatory protein, while the Lys414Ala and the

M. Veiga-da-Cunha et al.: Sensitivity of glucokinase to the regulatory protein

1177

Fig.5. Ribbon drawing of the a-carbon
backbone of the beta-cell human glucokinase based on the yeast hexokinase
structure in the open configuration. All
the amino acid mutations studied are
indicated. The residues in green correspond to mutations that do not affect
the affinity for the regulatory protein.
The residues in red and yellow correspond to the mutations that respectively decreased or increased the affinity for the regulatory protein. The residues in orange, Glu51and Glu52and the
loop Valls4 to Asp 158,were previously
shown [18] to decrease the affinity of
glucokinase for the regulatory protein
when replaced by corresponding residues in rat hexokinase I. The glucokinase model is represented using the
MOLSCRIPT software [29] and the coordinates of Charles et al. [30]
Asn166Arg mutants had an increased affinity for glucose compared to their respective controls, and a decreased affinity for the regulatory protein.
We have also tested the sensitivity of glucokinase
to long chain acylCoAs. All mutants, with two exceptions, displayed a sensitivity to palmitoylCoA that
was close, or identical, to that expressed by wildtype human glucokinases, which in turn was the
same as that of the rat liver enzyme. As shown in Figure 4, the Lys414Ala and the Glu279Gln mutants displayed a-~ 2.5-fold decrease in the sensitivity to this
effector.

Discussion
The mutation Asp15SAla was found in the expression
plasmids used in the present study as well as in the
c D N A produced by Nishi and co-workers [14]. It is
not known at present if this mutation results from a
PCR error (part of the complete c D N A produced by
Nishi and co-workers was obtained by amplification
with Taq polymerase) or from a cloning artifact. The
fact that Asp 158 is conserved among glucokinases
[18] and that the Ala 158 variant remained unnoticed
until now, despite intensive research of mutations in
the glucokinase gene, argues against a polymorphism.
The replacement of this residue by an alanine results in a significant increase in the affinity for glucose. This observation is not surprising since Asp ls8
is situated in the hinge region of glucokinase (Fig. 5)
close to residues Val 2°3 and Asn 2°4, which, when mutated to alanine and glutamine, respectively, lead to
enzymes with a very low affinity for glucose [20]

(Table 1). Furthermore it was found recently that the
replacement of residues Va1154 to Asp 158 by the corresponding residues of rat hexokinase I results in a tenfold decrease in the affinity for glucose [18].
The S0.5 value of the AsplSSAla mutant was consistently found in this work to be about 3.5 mmol/1 while
the " K i n " values mentioned in the literature for the
same enzyme (reported to be the wild-type enzyme)
range between 8 + 2 and 6 + 0.4 mmol/l [9-12]. This
inconsistency is not due to differences in the assay
conditions but most likely results from the use of inappropriate methods to calculate K m values for glucokinase (the term K m is actually meaningless for a
sigmoidal enzyme). It is well known that, for enzymes
with sigmoidal saturation curve, double-reciprocal
plots are curvilinear. The same is true for Hanes plots,
though the latter type of plot may give the wrong impression of linearity at elevated concentrations of
substrate. It can be demonstrated, however, that for
an enzyme responding to the Hill equation, there is
no linear portion in a Hanes plot if h ¢ 1. This is the
reason why different K m values are calculated depending on the set of data used (Fig. 3 b). In contrast,
the use of the Hill plot gives S0 5 values which are independent of the chosen data set (Fig. 3 a). The importance of correctly determining S0 5 values of glucokinase has been recently discussed by Cardenas
[211.
Previous work performed on xenopus glucokinase
indicated that the regulatory protein binds to the tip
of the small domain and to the hinge region of this enzyme [18]. Mutations of residues 51 and 52, as well as
of residues 141-144 resulted in a remarkable decrease in the affinity for the regulatory protein
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(Fig. 5). The results obtained in the present work confirm and extend these conclusions. Thus, the mutations that result in a decrease in the affinity for
the regulatory protein cluster in the hinge region
(Val2°3Ala, Asn2°4Gln), in close proximity to Glu 51
and Glu 52, and in the nearby regions of the small
(Asn166Arg) and the large domain (Lys414Ala; Fig. 5).
The increase in affinity induced by the Va1182Met mutation could be due to a change in the positioning of
the His141-Leu 144 loop, which appears to play an important role in the binding of the regulatory protein
[18]. The fact that the beta-cell enzyme and the liver
enzyme have the same affinity for the regulatory protein indicates that the fifteen N-terminal amino acids,
which are located in the large domain, are remote
from the regulatory protein binding site.
By binding to the hinge region, the regulatory protein is likely to interfere with the closure of the catalytic cleft, which appears to be a prerequisite for the
phosphoryl transfer reaction occurring between
A T P and glucose in hexokinases.
Until now, only two mutants have been found to
have a decreased affinity for palmitoylCoA. Both
mutations involve residues (Lys414 and Glu 279) that
are in the large domain of the enzyme. These results
indicate that the binding site for palmitoylCoA is
most likely on the "internal" face of the large domain
(Fig.5). The lack of synergism between palmitoylC o A and the regulatory protein [16] is probably due
to the fact their binding sites partially overlap in the
hinge region.
A growing body of evidence indicates that glucokinase plays a critical role in the control of insulin secretion by the beta cell. Insulin secretion correlates with
glucose metabolism in beta cells and glucokinase appears to be the rate-limiting enzyme of glycolysis in
these cells (reviewed in [22-24]). In addition, mutations of the glucokinase gene that result in the synthesis of inactive enzyme or enzyme with reduced activity
lead to a form of non-insulin-dependent diabetes
called MODY, which is characterized by a decreased
insulin secretion (reviewed in [25-26]). This condition
is inherited in an autosomal dominant fashion indicating that a 50 % decrease or even a decrease of smaller
magnitude in the activity of glucokinase is sufficient
to cause a significant reduction in insulin secretion.
The fact that islet glucokinase is sensitive to the
regulatory protein indicates that a similar type of
mechanism to that found in liver could operate in islet cells. Equally, since fructose 1-phosphate was
found to stimulate the activity of glucokinase in extracts of islets [6, 27], this indicates that these cells
could contain a regulatory protein that is similar or
related to that found in liver. Interestingly, low
amounts of regulatory protein m R N A were found in
rat islets [27]. However, it remains to be seen if the
concentration of regulatory protein is sufficient to exert a significant inhibition in vivo.

Sturis and co-workers [28] have shown that, in several subjects with mutations in the glucokinase gene,
insulin secretion was reduced compared to that in
control subjects but less than predicted from the calculated decrease in glucokinase flux, suggesting that
there are compensatory changes. One possibility is
upregulation of the glucokinase expression as a result
of the increase in the blood glucose level [26]. The
second possibility is a decrease in the inhibitory effect
of the regulatory protein. The present work shows
that this could be the case for the Val2°3Ala mutant,
which has a reduced affinity for the regulatory protein. Patients harbouring this mutation were found
to have reduced rates of insulin secretion but this reduction was less than predicted by loss of enzymic activity [26].
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